Epidermal growth factor receptor (EGFR) is the first growth factor receptor identified in normal cells that is related to the receptor tyrosine kinase, which causes regular cell division. A point mutation in EGFR intracellular kinase domain forces the abnormal cell divisions throughout time, leading to non-small cell lung cancer (NSCLC) transformation. Thus, competitive inhibitors that bind to the ATP binding pocket have been developed as a targeted therapy for NSCLC. The third-generation kinase inhibitor Osimertinib is currently playing a very vital role in the treatment of NSCLC. However, it is not effective toward the C797S kinase domain mutation. For this reason, fourth-generation kinase noncompetitive inhibitors are introduced which wo...
The non-small cell lung (NSCL) and colorectal cancers are frequently linked with the oncogenic activ...
Covalent modification of the oncogenic mutant epidermal growth factor receptor (EGFR) by small molec...
Wei Liu,1,* Jin-Feng Ning,2,* Qing-Wei Meng,1 Jing Hu,1 Yan-Bin Zhao,1 Chao Liu,3 Li Cai11The Fourth...
Epidermal growth factor receptor (EGFR) is the first growth factor receptor identified in normal cel...
Lung cancer is the leading cause of cancer death, and epidermal growth factor receptor (EGFR) kinase...
Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain give rise to s...
Over the last two decades epidermal growth factor receptor (EGFR) kinase has become an important tar...
645-650Molecules targeting non-small cell lung cancer driven by activating mutations within the epid...
Activation of cell surface growth factor receptor tyrosine kinases (RTKs) results in cellular prolif...
Epidermal growth factor receptor (EGFR) abnormalities have been associated with several types of hum...
Although the inhibitors of singly mutated epidermal growth factor receptor (EGFR) kinase are effecti...
Activation of cell surface growth factor receptor tyrosine kinases (RTKs) results in cellular prolif...
The overexpression or mutation of the kinase domain of the epidermal growth factor receptor (EGFR) i...
The discovery of mutations within the kinase domain of the epidermal growth factor receptor (EGFR) g...
Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers. In spite of great advances,...
The non-small cell lung (NSCL) and colorectal cancers are frequently linked with the oncogenic activ...
Covalent modification of the oncogenic mutant epidermal growth factor receptor (EGFR) by small molec...
Wei Liu,1,* Jin-Feng Ning,2,* Qing-Wei Meng,1 Jing Hu,1 Yan-Bin Zhao,1 Chao Liu,3 Li Cai11The Fourth...
Epidermal growth factor receptor (EGFR) is the first growth factor receptor identified in normal cel...
Lung cancer is the leading cause of cancer death, and epidermal growth factor receptor (EGFR) kinase...
Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain give rise to s...
Over the last two decades epidermal growth factor receptor (EGFR) kinase has become an important tar...
645-650Molecules targeting non-small cell lung cancer driven by activating mutations within the epid...
Activation of cell surface growth factor receptor tyrosine kinases (RTKs) results in cellular prolif...
Epidermal growth factor receptor (EGFR) abnormalities have been associated with several types of hum...
Although the inhibitors of singly mutated epidermal growth factor receptor (EGFR) kinase are effecti...
Activation of cell surface growth factor receptor tyrosine kinases (RTKs) results in cellular prolif...
The overexpression or mutation of the kinase domain of the epidermal growth factor receptor (EGFR) i...
The discovery of mutations within the kinase domain of the epidermal growth factor receptor (EGFR) g...
Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers. In spite of great advances,...
The non-small cell lung (NSCL) and colorectal cancers are frequently linked with the oncogenic activ...
Covalent modification of the oncogenic mutant epidermal growth factor receptor (EGFR) by small molec...
Wei Liu,1,* Jin-Feng Ning,2,* Qing-Wei Meng,1 Jing Hu,1 Yan-Bin Zhao,1 Chao Liu,3 Li Cai11The Fourth...